AlloVir (NASDAQ:ALVR) Hits New 1-Year Low – Time to Sell?

Shares of AlloVir, Inc. (NASDAQ:ALVR) hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $7.97 and last traded at $8.40, with a volume of 12995 shares trading hands. The stock had previously closed at $8.77.

AlloVir Stock Performance

The company has a fifty day moving average price of $0.84 and a two-hundred day moving average price of $0.80. The company has a market cap of $1.07 billion, a P/E ratio of -10.55 and a beta of 0.65.

AlloVir (NASDAQ:ALVR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, beating analysts’ consensus estimates of ($3.22) by $2.30.

Institutional Investors Weigh In On AlloVir

An institutional investor recently bought a new position in AlloVir stock. Point72 Asia Singapore Pte. Ltd. acquired a new stake in AlloVir, Inc. (NASDAQ:ALVR) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 76,278 shares of the company’s stock, valued at approximately $55,000. Point72 Asia Singapore Pte. Ltd. owned about 0.07% of AlloVir at the end of the most recent reporting period. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

AlloVir Company Profile

AlloVir, Inc engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.